We are delighted to launch our very own Brexit microsite today. The microsite shows the important work that the BIA has done in this crucial area and highlights the issues that matter most to our members.
Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed.
Super-fast product addresses critical unmet need in development of next generation
artificial pancreas systems”
“Novel formulation significantly accelerates absorption of insulin post injection - accelerating the onset of glucose lowering.”
RxCelerate, one of the leading outsourced drug discovery and development platforms in the United Kingdom, announced today that it has acquired U.K.-based molecular modelling company Prosarix. Originally founded in 2006, Prosarix has built a reputation as one of the leading exponents of molecular modelling, supporting both protein engineering and in silico drug design projects.
When Brexit seemingly takes up an ever-increasing amount of time and resources, it’s important (and perhaps even – dare I say it – refreshing) to remember there are other matters of great concern for the life sciences sector.
One of those matters is this year’s Spending Review (SR)– the process by which the Government decides how much each government department will spend within a given period. This has a major impact on our sector as public funding bodies, such as UK Research and Innovation (UKRI), its Councils and the National Institute for Health Research (NIHR), are funded through government departments.
Today is ‘International Day of Women and Girls in Science’, a day where we celebrate the fantastic work of women right across our sector. At the BIA we champion women’s role in science through our regular Women in Biotech Networking events, with the next one happening in March, while at our Gala Dinner this year I was delighted that Melanie Lee from Life Arc was awarded the BIA lifetime achievement award. There is some great material being shared online so do stay up to date on twitter using the hashtag #womeninscience and help inspire the next generation.
In 2018, Genomics England announced that they had successfully sequence the genomes of 100,000 individuals. This data provides an invaluable research tool, allowing us to gain insight into the impact of genetics on disease potential and drug efficacy. Genomics is at the very forefront of biotechnology and medicine.
BioCity, the UK’s largest life science incubator has been appointed by Newcastle City Council to run a life science accelerator and business support programme from The Biosphere, which is based on Newcastle Helix.
The Government last night committed to further consultation with the BIA on the UK’s future Intellectual Property rights regime in the event of a ‘no deal’ Brexit following concerns raised in the House of Lords.
Catapult enable UK life science companies to develop their drug discovery projects. If you are an SME with a drug discovery project, or a CRO with expertise to provide, join this webinar and find out how we can help you.